BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12182001)

  • 1. [Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
    Ostański M; Sońta-Jakimczyk D
    Wiad Lek; 2002; 55(3-4):164-73. PubMed ID: 12182001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
    Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
    Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
    Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
    N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.
    Lipshultz SE; Rifai N; Dalton VM; Levy DE; Silverman LB; Lipsitz SR; Colan SD; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE
    N Engl J Med; 2004 Jul; 351(2):145-53. PubMed ID: 15247354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Exercise tolerance in patients after acute lymphoblastic leukemia treatment in childhood].
    Ostański M; Sońta-Jakimczyk D
    Wiad Lek; 2001; 54(11-12):650-5. PubMed ID: 11928552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.
    Lipshultz SE; Miller TL; Scully RE; Lipsitz SR; Rifai N; Silverman LB; Colan SD; Neuberg DS; Dahlberg SE; Henkel JM; Asselin BL; Athale UH; Clavell LA; Laverdière C; Michon B; Schorin MA; Sallan SE
    J Clin Oncol; 2012 Apr; 30(10):1042-9. PubMed ID: 22370326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
    Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
    Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
    J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cardiac follow-up of children treated with anthracycline doses of 300 mg/m2 or less for acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H; Nielsen G
    Pediatr Blood Cancer; 2010 Mar; 54(3):444-8. PubMed ID: 19830828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of systolic and diastolic function of the left ventricle in children with acute lymphoblastic leukaemia before treatment].
    Jackowska T; Pleskot M; Gołabek M; Rokicka-Milewska R; Wróblewska-Kałuzewska M; Wypych A; Matysiak M; Klus K; Juraszewska E; Balwierz W; Wójcik B; Sadurska E; Kowalczyk J; Stencel D; Siwinska A; Wachowiak J; Szmyd K; Kukawczyńska E; Chybicka A; Płoszyńska A; Aleszewicz-Baranowska J; Balcerska A; Ostański M; Pobudejska A; Sońta-Jakimczyk D; Krenke K; Madry W; Syczewska M; Rudziński A
    Przegl Lek; 2004; 61 Suppl 2():70-5. PubMed ID: 15686051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
    Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
    Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
    Paiva MG; Petrilli AS; Moisés VA; Macedo CR; Tanaka C; Campos O
    Pediatr Blood Cancer; 2005 Dec; 45(7):902-8. PubMed ID: 16035077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
    Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
    J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Left ventricular mass and function in growth hormone deficient children and adolescents before and after one year of recombinant human growth hormone (GH) replacement therapy].
    Szczepańska Kostro J; Tołwińska J; Urban M; Głowińska B
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):75-80. PubMed ID: 15504309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug may protect children's hearts from chemotherapy.
    McBride D
    ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085
    [No Abstract]   [Full Text] [Related]  

  • 18. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
    Rathe M; Carlsen NL; Oxhøj H
    Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
    Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.